Skip to main content
. 2014 Jul;58(7):3626–3635. doi: 10.1128/AAC.00123-14

TABLE 1.

In vitro susceptibilities for clinical and mutant isolates included in the study and for quality-control strains, as determined by EUCAST or Etesta

Isolate type and mutant or strain EUCAST MIC (mg/liter) (susceptibility classification) forb:
Etest MIC (mg/liter) (susceptibility classification) forc:
ANI MICA VOR ISA FLU CAS AMB
Clinical isolates or QCd strain
    SCL 1130.04e <0.008 (S) <0.008 (S) 0.5 (R) 0.06 >16 (R) 0.125 (S) 0.5 (S)
    RRCL 110.1f 0.03 (S) >1 (R) 4 (R) 0.5 >16 (R) 2 (R) 0.5 (S)
    ATCC 22019g 0.125 (I) >1 (I) <0.03 (S) <0.03 2 (S) 0.5 (S) 0.38 (S)
Mutant isolates or QC strain
    SSWT SC5314h 0.015 (S) <0.008 (S) <0.03 (S) <0.03 0.25 (S) 0.19 (S) 0.25 (S)
    RRMH2h 0.06 (R) 0.03 (R)i <0.03 (S) <0.03 0.25 (S) 0.75 (R) 0.19 (S)
    RSMH1h 0.015 (S) 0.03 (R)j <0.03 (S) <0.03 <0.125 (S) 0.25 (S) 0.25 (S)
    SRMH1h 0.015 (S) 0.008 (S) <0.03 (S) <0.03 0.25 (S) 0.25 (S) 0.25 (S)
    RRMHO2h 0.06 (R) 1 (R)k <0.03 (S) <0.03 <0.125 (S) 1 (R) 0.38 (S)
    ATCC 6258g 0.06 (S) 0.125 0.125 (S) <0.03 16 (R) 0.38 (I) 0.75 (S)
a

Susceptibility classifications were performed according to the EUCAST breakpoints (BP), except for CAS and Etest, for which CLSI BP were adopted, as recommended by the manufacturer.

b

ANI, anidulafungin; MICA, micafungin; VOR, voriconazole; ISA, isavuconazole; FLU, fluconazole; S, susceptible; R, resistant; I, intermediate.

c

CAS, caspofungin; AMB, amphotericin B.

d

QC, quality control.

e

The clinical isolates 952.04 and 5104.04 revealed the same MICs within ±1 dilution step difference; these strains do not carry coding FKS1 HS1 or HS2 mutations.

f

The clinical isolate 111.12 revealed the same MIC within ±1 dilution step difference; these strains carry the mutations R647R/G and P649P/L.

g

Quality-control strains.

h

SC5314 is the wild-type parental strain; mutations carried by the strains are as follows: RRMH2, R647R/G and P649P/L; RSMH1, R647R/G; SRMH1, P649P/L; and RRMHO2, R647G and P649L.

i

Micafungin trailing 0.03 to 1 but stays at <50% endpoint in this range.

j

Micafungin creeping increase 0.03 to 0.25.

k

Micafungin trailing 0.06 to 0.25 and just >50% endpoint in this range.